Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent

Showing results (931-940 of 968) with videos related to

Pageof 97
Sort By:
Blood Advances|April 9, 2026
Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL AmyloidosisMaximilian Johannes Steinhardt, Eli Muchtar, Taxiarchis V Kourelis, et al.
Blood Cancer Journal|June 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myelomaBinoy Yohannan, Benjamin W Langworthy, Lindsey E Turner, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Nature Genetics|August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupAntonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, et al.
Blood|July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaJonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
American Journal of Hematology|January 11, 2021
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohortMaria Eleni Drosou, Lisa E Vaughan, Eli Muchtar, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple MyelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
The discovery of sulfonylated dipeptides as potent VLA-4 antagonistsW K Hagmann, P L Durette, T Lanza, et al.
Pageof 97

Showing results (931-940 of 968) with videos related to

Sort By:
Pageof 97
Blood Advances|April 9, 2026
Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL AmyloidosisMaximilian Johannes Steinhardt, Eli Muchtar, Taxiarchis V Kourelis, et al.
Blood Cancer Journal|June 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myelomaBinoy Yohannan, Benjamin W Langworthy, Lindsey E Turner, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Nature Genetics|August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupAntonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, et al.
Blood|July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaJonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
American Journal of Hematology|January 11, 2021
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohortMaria Eleni Drosou, Lisa E Vaughan, Eli Muchtar, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple MyelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
The discovery of sulfonylated dipeptides as potent VLA-4 antagonistsW K Hagmann, P L Durette, T Lanza, et al.
Pageof 97